AstraZeneca PLC (AZN)vsbiote Corp (BTMD)
AZN
AstraZeneca PLC
$185.48
-0.59%
HEALTHCARE · Cap: $293.73B
BTMD
biote Corp
$1.03
-5.50%
HEALTHCARE · Cap: $37.63M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 33891% more annual revenue ($62.38B vs $183.53M). AZN leads profitability with a 17.7% profit margin vs 3.2%. BTMD trades at a lower P/E of 7.9x. AZN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy68
out of 100
Grade: B-
BTMD
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$185.48
$12.46 discount
Margin of Safety
+45.4%
Fair Value
$3.88
Current Price
$1.03
$2.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
3.2% margin — thin
Revenue declined 9.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bull Case : BTMD
The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : BTMD
The primary concerns for BTMD are Market Cap, Return on Equity, Profit Margin. Thin 3.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while BTMD is a value play — different risk/reward profiles.
BTMD carries more volatility with a beta of 1.69 — expect wider price swings.
AZN is growing revenue faster at 6.7% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (68/100 vs 33/100), backed by strong 17.7% margins. BTMD offers better value entry with a 45.4% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
biote Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
biote corp. The company is headquartered in Irvine, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?